Latest News about AZN
Recent news which mentions AZN
China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
June 26, 2024
From Benzinga
From Benzinga
From InvestorPlace
From Benzinga
From InvestorPlace
From InvestorPlace
3 No-Brainer Stocks to Buy for Under $100 Right Now
June 22, 2024
From Motley Fool
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
From Benzinga
From Benzinga
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial
June 18, 2024
From Benzinga
From Benzinga
From Benzinga
3 Best Stocks to Buy From the Fantastic 5
June 17, 2024
From InvestorPlace
From Benzinga
3 Crazy Good Stocks to Buy With $500 Right Now
June 12, 2024
From InvestorPlace
From InvestorPlace
From InvestorPlace
From Benzinga
From Motley Fool
3 No-Brainer Stocks to Buy in June
June 02, 2024
From Motley Fool
Tickers
AZN
From Motley Fool
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
May 29, 2024
From Benzinga
From Motley Fool
Tickers
AZN
From Motley Fool
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
From Benzinga
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
May 27, 2024
From Benzinga
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies
May 23, 2024
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free